AtriCure, Inc. Reports Strong Q1 2025 Growth

Atricure, Inc. ( (ATRC) ) has released its Q1 earnings. Here is a breakdown of the information Atricure, Inc. presented to its investors.

AtriCure, Inc. is a leading company in the medical device sector, specializing in innovative surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management. The company is recognized for its FDA-approved devices and minimally invasive procedures that address persistent atrial fibrillation and related conditions.

In its first quarter of 2025, AtriCure reported a worldwide revenue of $123.6 million, marking a 13.6% increase compared to the previous year. The company also saw a significant improvement in its net loss, which decreased by $6.5 million year over year, alongside an increase in adjusted EBITDA by $6.0 million.

Key financial highlights include a 12.1% growth in U.S. revenue, driven by strong sales across major product lines such as the EnCompass clamp and cryoSPHERE MAX probes. International revenue also saw a substantial increase of 20.8%, reflecting the global adoption of AtriCure’s innovative products. The company achieved a gross profit of $92.6 million, with a gross margin improvement to 74.9%.

Looking ahead, AtriCure projects its full-year 2025 revenue to be between $517 million and $527 million, with an expected adjusted EBITDA of approximately $44 million to $46 million. The company anticipates modest cash flow generation for the year, as it continues to focus on expanding its market presence and profitability through innovation and clinical evidence generation.